Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR‐RA) Study-Reference-Cited by-同舟云学术

Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR‐RA) Study

Published:2022-09 Issue:10 Volume:74 Page:1648-1659
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Khosrow‐Khavar Farzin¹^ORCID,Desai Rishi J.¹,Lee Hemin¹^ORCID,Lee Su Been¹,Kim Seoyoung C.²^ORCID

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics Brigham and Women's Hospital, and Harvard Medical School Boston Massachusetts

2. Division of Pharmacoepidemiology and Pharmacoeconomics, and Division of Rheumatology, Inflammation, and Immunity Brigham and Women's Hospital, and Harvard Medical School Boston Massachusetts

Funder

NIH

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.42250

Reference46 articles.

1. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017

2. Brigham and Women's Hospital sponsor.Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR‐RA)‐cardiovascular endpoints.ClinicalTrials.govidentifier: NCT04772248;2021.

3. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

4. Utilization of targeted disease-modifying anti-rheumatic drugs (DMARDs) for managing rheumatoid arthritis in the last decade:  A two-country comparison

5. Pfizer Inc sponsor.Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis.ClinicalTrials.govidentifier: NCT02092467;2014.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and Factors Associated with De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis: A Medicare Claims-Based Observational Study;Drugs & Aging;2024-06-20

2. Sécurité d’utilisation des inhibiteurs de Jak : actualités;La Revue de Médecine Interne;2024-06

3. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis;Expert Opinion on Drug Safety;2024-05-23

4. Prevalence of Cardiovascular and Cancer Risk Factors Among Rheumatoid Arthritis Patients Prescribed JAK Inhibitors and Tumor Necrosis Factor Inhibitors: A Cross‐Sectional Study;Arthritis Care & Research;2024-05-21

5. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19